Darryl Toth

3.2k total citations · 1 hit paper
33 papers, 1.7k citations indexed

About

Darryl Toth is a scholar working on Dermatology, Immunology and Immunology and Allergy. According to data from OpenAlex, Darryl Toth has authored 33 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Dermatology, 17 papers in Immunology and 12 papers in Immunology and Allergy. Recurrent topics in Darryl Toth's work include Dermatology and Skin Diseases (26 papers), Psoriasis: Treatment and Pathogenesis (17 papers) and Asthma and respiratory diseases (9 papers). Darryl Toth is often cited by papers focused on Dermatology and Skin Diseases (26 papers), Psoriasis: Treatment and Pathogenesis (17 papers) and Asthma and respiratory diseases (9 papers). Darryl Toth collaborates with scholars based in Canada, United States and Poland. Darryl Toth's co-authors include Craig L. Leonardi, Kim Papp, Mark Lebwohl, Scott D. Glazer, Alan Menter, Richard G. Langley, Jacek C. Szepietowski, David M. Pariser, Stephen K. Tyring and Tiffani K. Hamilton and has published in prestigious journals such as New England Journal of Medicine, Journal of Allergy and Clinical Immunology and Journal of the American Academy of Dermatology.

In The Last Decade

Darryl Toth

32 papers receiving 1.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

2021 199 citations Kim Papp, Jacek C. Szepietowski et al. Journal of the American Academy of Dermatology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Darryl Toth	1.2k	954	329	321	283	33	1.7k
M. Lahfa	933 0.8×	1.1k 1.1×	359 1.1×	235 0.7×	204 0.7×	22	1.6k
Luca Potestio	778 0.7×	839 0.9×	127 0.4×	142 0.4×	220 0.8×	114	1.4k
Tiffani K. Hamilton	829 0.7×	505 0.5×	127 0.4×	165 0.5×	221 0.8×	25	1.2k
Michael Song	2.1k 1.8×	1.3k 1.3×	114 0.3×	682 2.1×	298 1.1×	49	2.5k
Angelo Ruggiero	1.0k 0.8×	893 0.9×	51 0.2×	158 0.5×	266 0.9×	101	1.6k
Melodie Young	1.0k 0.9×	575 0.6×	51 0.2×	223 0.7×	245 0.9×	41	1.3k
Isabelle Hampele	1.3k 1.1×	751 0.8×	40 0.1×	344 1.1×	261 0.9×	8	1.6k
Mary Flack	1.3k 1.1×	822 0.9×	38 0.1×	194 0.6×	200 0.7×	25	1.5k
Marianne Notter	1.3k 1.1×	732 0.8×	39 0.1×	342 1.1×	250 0.9×	9	1.6k
Yoshinori Umezawa	857 0.7×	551 0.6×	41 0.1×	252 0.8×	159 0.6×	71	1.3k

Countries citing papers authored by Darryl Toth

Since Specialization

Citations

This map shows the geographic impact of Darryl Toth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darryl Toth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darryl Toth more than expected).

Fields of papers citing papers by Darryl Toth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darryl Toth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darryl Toth. The network helps show where Darryl Toth may publish in the future.

Co-authorship network of co-authors of Darryl Toth

This figure shows the co-authorship network connecting the top 25 collaborators of Darryl Toth. A scholar is included among the top collaborators of Darryl Toth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darryl Toth. Darryl Toth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bissonnette, Robert, Jennifer Soung, Adelaide A. Hebert, et al.. (2025). Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. New England Journal of Medicine. 393(18). 1784–1795.

Gold, Linda Stein, Javier Alonso‐Llamazares, Zoe Draelos, et al.. (2022). Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial. American Journal of Clinical Dermatology. 24(2). 305–313. 9 indexed citations

Blauvelt, Andrew, Richard G. Langley, J.‐P. Lacour, et al.. (2022). Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial. Journal of the American Academy of Dermatology. 87(4). 815–824. 48 indexed citations

Papp, Kim, Jacek C. Szepietowski, Leon Kircik, et al.. (2022). Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies. Journal of the American Academy of Dermatology. 88(5). 1008–1016. 58 indexed citations

Papp, Kim, Jacek C. Szepietowski, Leon Kircik, et al.. (2021). Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. Journal of the American Academy of Dermatology. 85(4). 863–872. 199 indexed citations breakdown →

Papp, Kim, Jacek C. Szepietowski, Leon Kircik, et al.. (2021). Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind Studies. SKIN The Journal of Cutaneous Medicine. 5(1). s8–s8. 1 indexed citations

Papp, Kim, Jacek C. Szepietowski, Leon Kircik, et al.. (2020). Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies. SKIN The Journal of Cutaneous Medicine. 4(6). s95–s95. 17 indexed citations

Langley, Richard G., Kristian Reich, Vibeke Strand, et al.. (2019). Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Quality of Life Research. 29(2). 369–380. 4 indexed citations

Mrowietz, Ulrich, Craig L. Leonardi, Giampiero Girolomoni, et al.. (2015). Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). Journal of the American Academy of Dermatology. 73(1). 27–36.e1. 170 indexed citations

10.

Kunynetz, Rod, et al.. (2011). Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study. European Journal of Dermatology. 21(1). 89–94. 10 indexed citations

11.

Langley, Richard G., Kim Papp, Robert Bissonnette, et al.. (2010). Safety profile of intravenous and subcutaneous siplizumab, an anti‐CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double‐blind, placebo‐controlled studies. International Journal of Dermatology. 49(7). 818–828. 22 indexed citations

12.

Papp, Kim, Yves Poulin, Robert Bissonnette, et al.. (2010). Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. Journal of the American Academy of Dermatology. 66(2). e33–e45. 80 indexed citations

13.

Toth, Darryl, Kim Papp, & David Gratton. (2008). Long-term efficacy of up to 15 months’ efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis. Dermatologic Therapy. 21. S6–S14. 4 indexed citations

14.

Menter, Alan, Tiffani K. Hamilton, Darryl Toth, et al.. (2007). Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open‐label, multicenter, Phase IIIb study. International Journal of Dermatology. 46(6). 637–648. 27 indexed citations

15.

Leonardi, Craig L., Darryl Toth, Jennifer Clay Cather, et al.. (2006). A Review of Malignancies Observed during Efalizumab (Raptiva®) Clinical Trials for Plaque Psoriasis. Dermatology. 213(3). 204–214. 37 indexed citations

16.

Gordon, Kenneth B., Richard G. Langley, Craig L. Leonardi, et al.. (2006). Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. Journal of the American Academy of Dermatology. 55(4). 598–606. 407 indexed citations

17.

Carey, Wayne, Scott D. Glazer, Alice B. Gottlieb, et al.. (2006). Relapse, rebound, and psoriasis adverse events: An advisory group report. Journal of the American Academy of Dermatology. 54(4). S171–S181. 115 indexed citations

18.

Papp, Kim, et al.. (2006). Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. BMC Dermatology. 6(1). 9–9. 12 indexed citations

19.

Lebwohl, Mark, Stephen K. Tyring, Tiffani K. Hamilton, et al.. (2003). A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis. New England Journal of Medicine. 349(21). 2004–2013. 424 indexed citations

20.

Toth, Darryl, et al.. (1996). SKIN AND DIABETES. Endocrinology and Metabolism Clinics of North America. 25(2). 463–472. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact